Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Christian M. Vonk"'
Autor:
Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk
Publikováno v:
HemaSphere, Vol 8, Iss 8, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/e4ace97ccecf4ac7a3b83065bfbd9adb
Autor:
Tim Grob, Mathijs A. Sanders, Christian M. Vonk, Franҫois G. Kavelaars, Melissa Rijken, Diana W. Hanekamp, Patrycja L. Gradowska, Jacqueline Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Violaine Havelange, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J.M. Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4):JCO2200715, 756-765. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
PURPOSE The applicability of FLT3-internal tandem duplications ( FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential ins
Autor:
Tim, Grob, Mathijs A, Sanders, Christian M, Vonk, Franҫois G, Kavelaars, Melissa, Rijken, Diana W, Hanekamp, Patrycja L, Gradowska, Jacqueline, Cloos, Yngvar, Fløisand, Marinus, van Marwijk Kooy, Markus G, Manz, Gert J, Ossenkoppele, Lidwine W, Tick, Violaine, Havelange, Bob, Löwenberg, Mojca, Jongen-Lavrencic, Peter J M, Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
The applicability ofIn 161 patients with de novoNGS-basedNGS-based detection of
Autor:
Valentina M. Gomez, Carlotta Granchi, Marika Franczak, Mjriam Capula, Ryszard T. Smolenski, Elisa Giovannetti, Filippo Minutolo, Christian M. Vonk, Btissame El Hassouni, Godefridus J. Peters
Publikováno v:
Oncoscience
Direct targeting of energy metabolism to defeat cancer is not a recent strategy. Although quite a few drugs use cellular metabolism for their antitumor effect, no direct inhibitors of energy metabolism have been approved by the FDA. Currently, severa
Autor:
François G. Kavelaars, Elvira Verhoef, Bianca Venniker-Punt, Peter J. M. Valk, Christian M. Vonk, Pauline A. Merle, Zinia J. Kwidama, Jacqueline Cloos, Patrycja L Gradowska, Jeroen Janssen, David G. J. Cucchi, Bob Löwenberg, Melissa Rijken
Publikováno v:
Cucchi, D G, Vonk, C M, Rijken, M, Kavelaars, F, Merle, P, Verhoef, E, Venniker-Punt, B, Kwidama, Z J, Gradowska, P, Löwenberg, B, Janssen, J J W M, Cloos, J & Valk, P J M 2021, ' DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia ', BLOOD ADVANCES, vol. 5, no. 21, pp. 4476-4479 . https://doi.org/10.1182/bloodadvances.2021004980
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Blood Advances
Blood advances, 5(21), 4476-4479. American Society of Hematology
BLOOD ADVANCES, 5(21), 4476-4479. American Society of Hematology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b787f38dc96d2345cc2e518086b31a
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
https://research.vumc.nl/en/publications/0a7b0550-67cd-4a96-a66d-a7a25142ae3d
Publikováno v:
Cancers, Vol 13, Iss 5431, p 5431 (2021)
Vonk, C M, Al Hinai, A S A, Hanekamp, D & Valk, P J M 2021, ' Molecular minimal residual disease detection in acute myeloid leukemia ', Cancers, vol. 13, no. 21, 5431 . https://doi.org/10.3390/cancers13215431
Cancers
Vonk, C M, Al Hinai, A S A, Hanekamp, D & Valk, P J M 2021, ' Molecular minimal residual disease detection in acute myeloid leukemia ', Cancers, vol. 13, no. 21, 5431 . https://doi.org/10.3390/cancers13215431
Cancers
Simple Summary Although the majority of patients with acute myeloid leukemia (AML) reach a morphologic complete remission after high-dose chemotherapy, the majority of them face a relapse within a few years. Detection of residual cells, persisting in
Autor:
Btissame El Hassouni, Rocco Sciarrillo, Valentina Edith Gómez, Mina Maftouh, Giulia Mantini, Christian M. Vonk, Carlotta Granchi, Niccola Funel, Filippo Minutolo, Godefridus J. Peters, Elisa Giovannetti
Pancreatic ductal adenocarcinoma (PDAC) is an abysmal disease with a 5-year survival rate of merely 8%. The tumor microenvironment of PDAC is one of the factors contributing to drug resistance. More specifically, the hypoxic tumor core and the metabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::097f847c349b699526900124e96c7284
http://hdl.handle.net/11568/1011421
http://hdl.handle.net/11568/1011421